Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
Volume 1.01M
Average 1.83M
CRBU Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Caribou Biosciences, Inc.NASDAQ: CRBU
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue falls 64.9% from a year ago
Deferred revenue stood at $994K at the end of Q1 FY2026, down 64.9% from a year earlier and down 47.5% from the prior quarter. Over 3 fiscal years it compounded at -42.4% a year.
Context
- Deferred revenue amounted to 0.7% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
- Deferred revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -64.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 1.9M USD
- Year-over-year change
- -39.4%
- 4-year CAGR
- -31.7%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.9M | -39.4% |
| FY2024 | 2024-12-31 | 3.13M | +9.9% |
| FY2023 | 2023-12-31 | 2.85M | -71.3% |
| FY2022 | 2022-12-31 | 9.94M | +14.2% |
| FY2021 | 2021-12-31 | 8.7M | — |
Deferred Revenue vs competitors
How CRBU compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -64.9% is the 2nd highest of 3, against a peer median of -49.4%.
- Deferred revenue amounts to 0.7% of total assets for CRBU, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $52.3M USD | +1.2% | +9.6% | 23.5% | |
| Mar 2026 | $30.95M USD | — | — | 25.9% | |
| Mar 2026 | $5.72M USD | — | — | 4.2% | |
| Mar 2026 | $994K USD | -64.9% | -42.4% | 0.7% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Dec 2025 | €0 EUR | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CRBU) | — | -49.4% | +9.6% | 0.0% | |
Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 240.42M | 58.34M | 51.16M | 16.29M | 12.36M |
| Short-term Investments | 135.41M | 189.33M | 277.67M | 193.24M | 126.98M |
| Net Receivables | 8.12M | 4.66M | 3.86M | 3.25M | 2.98M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 671K | 1.12M | 1.22M | 1.78M | 2.91M |
| Total Current Assets | 391.19M | 260.25M | 338.84M | 219.38M | 145.23M |
| Property, Plant & Equipment (Net) | 4.89M | 34.91M | 40.45M | 39.29M | 24.43M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 45.3M | 77.07M | 51.33M | 49.13M | 3.55M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 975K | 1.54M | 1.59M | 5.52M | 2.15M |
| Total Non-current Assets | 51.16M | 113.52M | 93.37M | 93.94M | 30.14M |
| Total Assets | 442.36M | 373.77M | 432.21M | 313.31M | 175.37M |
| Account Payables | 3.99M | 1.15M | 3.12M | 2.48M | 5.78M |
| Short-term Debt | 259K | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 8.7M | 9.94M | 2.85M | 3.13M | 1.9M |
| Other Current Liabilities | 4.75M | 7.12M | 10.62M | 10.22M | 8.56M |
| Total Current Liabilities | 25.83M | 28.13M | 28.3M | 30.65M | 25.41M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 476K | 381K | 557K | 548K | 4.27M |
| Deferred Revenue (Non-current) | 22.03M | 15.95M | 6.1M | 3.32M | 1.75M |
| Other Non-current Liabilities | 6.19M | 1.65M | 2.94M | 785K | (4.27M) |
| Total Non-current Liabilities | 28.7M | 44.77M | 35.51M | 29.71M | 27.78M |
| Total Liabilities | 54.53M | 72.89M | 63.81M | 60.36M | 53.19M |
| Common Stock | 6K | 6K | 8K | 9K | 9K |
| Retained Earnings | (97.79M) | (197.22M) | (299.29M) | (448.39M) | (596.52M) |
| Accumulated OCI | (135K) | (1.52M) | 30K | 255K | 103K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 387.83M | 300.87M | 368.4M | 252.95M | 122.18M |
| Total Debt | 259K | 27.75M | 27.11M | 26.49M | 27.23M |
| Net Debt | (240.42M) | (30.59M) | (24.05M) | 10.19M | 14.87M |
Caribou Biosciences, Inc.
NASDAQ:CRBU
Intrinsic Alpha fair value
Locked
Current Price
$0.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.